N/A
N=48
The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension
Chronic Thromboembolic Pulmonary Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT04773028 ↗Enrolled (actual)
48
Serious AEs
—
Results posted
Aug 2021
Primary outcome: Primary: Concentration of Matrix Metalloproteinase 2 and 9 Enzymes — 89289.89; 86548.72; 205707.83; 152911.57 ng/ml — p=<0.05
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- matrix metalloproteinase enzymes 2 and 9 (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- AHMET ZENGIN
- Primary completion
- May 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Concentration of Matrix Metalloproteinase 2 and 9 Enzymes |
89289.89; 86548.72; 205707.83; 152911.57; 88975.83; 182029.76 | <0.05 sig |
Summary
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension
Eligibility Criteria
Inclusion Criteria
- Despite 3 months of anticoagulation therapy
- mean pulmonary arterial pressure > 20 mmHg
- pulmonary vasculary resistance > 3 wood
- pulmonary capillary wedge pressure < 15 mmHg
- perfusion defect in ventilation perfusion scintigraphy
- pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions
Exclusion Criteria
- Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery
- Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease
Data sourced from ClinicalTrials.gov (NCT04773028). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.